Clinical trials: Lower Urinary Tract Disorder
- Condition Lower Urinary Tract Disorder
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Overactive Bladder, Neurogenic Detrusor Overactivity
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
- Trial name
- NCT00857896
- Testing
- Fesoterodine
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer
Urinary Incontinence
Evaluation Trial of Handheld Urinal for Adult Use
Usability and efficacy evaluation of a prototype handheld urinal for adult use
- Trial name
- NCT04897932
- Testing
- RS - WP06
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Binding Sciences Limited
Prostate Cancer
Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues
The intention of this study is to investigate how many patients with prostate cancer, planned to be treated with LHRH analogues without history of surgery or radiotherapy, are suffering from LUTS.
- Trial name
- ANALUTS (NCT02542501)
- Where
- 32 sites in Portugal, Spain
- Volunteers
- 470 people
- Sponsor
- Ipsen
Urinary Incontinence
Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
This study will evaluate the 3 doses of onabotulinumtoxinA (botulinum toxin Type A) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in pediatric participants between the ages of 5 to 17 years to…
- Trial name
- NCT01852045
- Testing
- OnabotulinumtoxinA
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 114 people
- Sponsor
- Allergan
Incontinence, Urge
T-DOC® 5 Fr Pediatric Clinical Investigation
A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
- Trial name
- NCT03429270
- Testing
- TDOC 5Fr
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Laborie Medical Technologies Inc.
Prostatic Hyperplasia
The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)
Study to assess efficacy, tolerability and safety parameters of a three month ALNA®OCAS® -treatment with special respect to nocturia
- Trial name
- NCT02245542
- Testing
- ALNA®OCAS®
- Volunteers
- 5,775 people
- Sponsor
- Boehringer Ingelheim
Neurogenic Detrusor Overactivity
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity
This study will evaluate the pharmacodynamics and pharmacokinetics of darifenacin liquid oral suspension in children, ages 2-15 years, with neurogenic detrusor overactivity.
- Trial name
- NCT00712322
- Testing
- Darifenacin
- Where
- 12 sites in United States, Colombia
- Volunteers
- 35 people
- Sponsor
- Warner Chilcott
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Refractory Overactive Bladder
A Study to Compare the Efficacy and Safety of Ultrasound Guided Lead Implantation for Sacral Neuromodulation (SNM) in Subjects With Overactive Bladder (OAB) With X-Ray Guided Technique
Overactive bladder(OAB,Urgency) was determined by International Continence Society as Urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract…
- Trial name
- NCT02946723
- Testing
- ultrasound, X-ray
- Volunteers
- 30 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Overactive Bladder
Post Marketing Survey of Vesicare in Japan
This study is to evaluate the effect of Vesicare on quality of life (QOL) in female patients.
- Trial name
- SET-Q (NCT01489709)
- Testing
- Vesicare
- Where
- 8 sites in Japan
- Volunteers
- 1,160 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia, Localized Prostate Cancer
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are…
- Trial name
- NCT06051942
- Testing
- Robotic Waterjet Treatment
- Where
- 6 sites in United States, Hong Kong and 2 more
- Volunteers
- 125 people
- Sponsor
- PROCEPT BioRobotics
Overactive Detrusor, Neurogenic Bladder
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition.
- Trial name
- NCT01192568
- Testing
- Oxybutynin
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- AbbVie
Overactive Bladder
Drug Use-Results Survey of Betanis Tablets in Japan
This study is to determine the following information. 1. The occurrence of adverse drug reactions in clinical settings. 2. Factors potentially impacting safety, effectiveness, and other aspects.
- Trial name
- NCT01919047
- Testing
- Betanis
- Where
- 8 sites in Japan
- Volunteers
- 10,711 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Specified Drug Use-results Survey of Betanis Tablets
To investigate the effects of mirabegron on the symptoms of glaucoma in overactive bladder (OAB) patients with coexisting glaucoma.
- Trial name
- NCT01898624
- Testing
- mirabegron
- Where
- 7 sites in Japan
- Volunteers
- 300 people
- Sponsor
- Astellas Pharma Inc
Urinary Incontinence, Urinary Bladder
OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)
This was a multicenter, randomized, double-blind, parallel-group, multiple-dose study to evaluate the efficacy and safety of BOTOX in adolescents with urinary incontinence due to overactive bladder (OAB) with inadequate…
- Conditions
- Urinary Incontinence, Urinary Bladder, Overactive
- Trial name
- NCT02097121
- Testing
- BOTOX®
- Where
- 39 sites in United States, Australia and 11 more
- Volunteers
- 56 people
- Sponsor
- Allergan
Urge Incontinence, Urinary Retention
Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control
The purpose of this study is assess the long-term safety and effectiveness of the InterStim tined lead using a minimally invasive approach.
- Trial name
- NCT00225966
- Testing
- Device Medtronic InterStim Tined Leads Models 3889 and 3093
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance…
- Trial name
- POTTOR (NCT01488578)
- Testing
- Tolterodine tartrate
- Volunteers
- 11,157 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder, Neurogenic Detrusor Overactivity
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
The purpose of the study is to evaluate the pharmacokinetics (PK) of mirabegron oral suspension after single dose administration in children with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB).
- Trial name
- NCT02526979
- Testing
- mirabegron
- Where
- 3 sites in Denmark, Poland
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Bladder, Overactive
Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents
This single-dose study will investigate how well solifenacin suspension is taken up, how long it stays in the body and how well it will be tolerated in children and adolescents aged 5-17 years with symptoms of overactive bladder.
- Trial name
- NCT01262391
- Testing
- Solifenacin succinate suspension 2.5 mg, Solifenacin succinate suspension 5 mg, Solifenacin succinate suspension 10 mg
- Where
- 8 sites in Belgium, Denmark and 2 more
- Volunteers
- 42 people
- Sponsor
- Astellas Pharma Inc
Neurogenic Detrusor Overactivity, Overactive Bladder
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
The purpose of this study is to evaluate the pharmacokinetics as well as the safety and tolerability of mirabegron OCAS tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB.
- Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder, Pharmacokinetics of Mirabegron
- Trial name
- NCT02211846
- Testing
- Mirabegron
- Where
- 13 sites in Belgium, Denmark and 3 more
- Volunteers
- 34 people
- Sponsor
- Astellas Pharma Inc